This suppression weakens the antitumor activity of T cells, thereby compromising the effectiveness of immunotherapy and resulting in a lower response rate in ovarian cancer compared to other malignancies (49).Secondly, the efficacy of PD-1/PDL1 inhibitors as monotherapy remains controversial. The gene discussed is CD274; the disease is ovarian cancer.